Clinical Trial Update: Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial update on safety and efficacy of abicipar pegol in neovascular age-related macular degeneration has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Abicipar Pegol (Abicipar Pegol)

Snippet

Sponsor: Allergan | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2020-07-30